文献速递前列腺癌

基于肿瘤的突变谱预测前列腺癌患者的内脏转移结局和早期死亡

Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
PubMed 文献 · Eur Urol Oncol · 2024-01-05

本研究纳入200例转移性前列腺癌患者,对111个基因及分子特征进行基因组分析,获得173例(87%)基因组谱。中位随访76个月期间84例(49%)死亡。TP53及Wnt通路基因(APC/CTNNB1)突变与内脏转移播散和早期死亡相关。

要点

  • TP53突变与内脏转移风险显著相关(p < 0.001),APC突变亦相关(p = 0.002)。
  • CTNNB1(p = 0.001)、TP53(p = 0.015)、BRCA2(p = 0.027)、FANC(p = 0.005)突变与更早死亡年龄显著相关。
  • TP53突变在欧洲血统患者中频率(42%)高于非洲血统患者(16%)。

核心结论

  • TP53基因及Wnt通路相关基因(APC/CTNNB1)突变与转移性内脏播散和早期死亡相关,这些基因组改变可考虑作为识别高危致死性疾病患者的标志物,后者可能从更强化治疗或新靶向治疗中获益。

研究设计与样本

  • 回顾性研究,选取200例转移性前列腺癌患者,采用MyChoice检测(Myriad Genetics公司)对111个基因及分子特征(同源重组缺陷[HRD]、微卫星不稳定性、肿瘤负荷突变)进行基因组分析。

主要发现

  • 获得173例(87%)基因组谱,中位随访76个月期间84例(49%)死亡。
  • TP53是最常突变的基因,其次是FANC基因(包括BRCA2)及Wnt通路基因(APC/CTNNB1)。
  • TP53突变在欧洲血统患者中频率为42%,高于非洲血统患者的16%。
  • HRD评分>25可预测FANC基因突变。
  • TP53(p < 0.001)和APC(p = 0.002)基因突变状态与内脏转移风险显著相关。

局限性

  • 回顾性研究设计,基于特定基因选择,且某些分子事件频率较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Visceral metastases are known to occur in advanced prostate cancer, usually when the tumour is resistant to androgen deprivation and, have worse outcomes regardless of therapies. OBJECTIVE: To analyse genomic alterations in tumour samples according to their lymphatic, bone, and visceral metastatic stages and overall survival. DESIGN, SETTING, AND PARTICIPANTS: We selected 200 patients with metastatic prostate cancer. Genomic profiling of 111 genes and molecular signatures (homologous recombination deficiency [HRD], microsatellite instability, and tumour burden mutation) was performed with the MyChoice test (Myriad Genetics, Inc, Salt Lake City, UT, USA). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The association between genomic profiles and visceral metastatic evolution was evaluated using logistic regression. Kaplan-Meier and Cox proportional hazard analyses were used for analyses of early death. RESULTS AND LIMITATIONS: A total of 173 (87%) genomic profiles were obtained. Eighty-four (49%) patients died during the follow-up period (median duration = 76 mo). TP53 was the most frequently mutated gene, followed by FANC genes, including BRCA2, and those of the Wnt-pathway (APC/CTNNB1). TP53 gene mutations were more frequent in patients of European (42%) than in those of African (16%) ancestry. An HRD score of >25 was predictive of FANC gene mutations. The mutational status of TP53 (p < 0.001) and APC (p = 0.002) genes were significantly associated with the risk of visceral metastases. The mutational status of CTNNB1 (p = 0.001), TP53 (p = 0.015), BRCA2 (p = 0.027), and FANC (p = 0.005) genes were significantly associated with an earlier age at death. The limitations are the retrospective study design based on a selection of genes and the low frequency of certain molecular events. CONCLUSIONS: Mutations in the TP53 gene and genes (APC/CTNNB1) related to the Wnt pathway are associated with metastatic visceral dissemination and early death. These genomic alterations could be considered as markers to identify prostate cancer patients at a high risk of life-threatening disease who might benefit from more intensified treatment or new targeted therapies. PATIENT SUMMARY: In this report, we evaluated the relationships between genomic profiles (gene mutations and molecular signatures) of tumour samples from patients with metastatic prostate cancer and early death. We found that mutations of specific genes, notably TP53 and APC/CTNNB1 related to the Wnt pathway, are associated with visceral metastatic progression and an earlier age at death.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Cussenot O, Timms KM, Perrot E, et al. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients. Eur Urol Oncol. 2024. PMID: 38182487. doi:10.1016/j.euo.2023.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。